Injectsense
Injectsense is a sensor-enabled digital health company specializing in implantable, ultra-miniature sensors that provide continuous, long-term physiological data for disease management, particularly in ophthalmology for glaucoma. Their mission is to revolutionize therapy effectiveness assessment through innovative microelectronics and medical systems, enabling proactive, data-driven healthcare.
Industries
Nr. of Employees
small (1-50)
Injectsense
2000 Powell St, Suite 1425, Emeryville, CA 94608
Patents
Products
Ultra‑miniature implantable sensor module for continuous intraocular pressure monitoring
A hermetically sealed, injectable implantable sensor module integrating a MEMS pressure sensor, ultra‑low power IC, solid‑state microbattery and wireless telemetry to log intraocular pressure continuously and upload encrypted data via a wearable reader and mobile app.
Modular implantable sensor platform for multi‑organ pressure and physiologic monitoring
A versatile, wafer‑scale manufactured sensor module adaptable to measure absolute pressure, flow, oxygenation, motion, electrical signals and temperature across multiple clinical domains (ophthalmic, neurosurgery, cardiovascular).
Ultra‑miniature implantable sensor module for continuous intraocular pressure monitoring
A hermetically sealed, injectable implantable sensor module integrating a MEMS pressure sensor, ultra‑low power IC, solid‑state microbattery and wireless telemetry to log intraocular pressure continuously and upload encrypted data via a wearable reader and mobile app.
Modular implantable sensor platform for multi‑organ pressure and physiologic monitoring
A versatile, wafer‑scale manufactured sensor module adaptable to measure absolute pressure, flow, oxygenation, motion, electrical signals and temperature across multiple clinical domains (ophthalmic, neurosurgery, cardiovascular).
Services
Partnerships with academic clinical centers for bench, animal and first‑in‑human pilot studies to collect safety and performance data.
Transfer of semiconductor‑based implant designs to wafer‑scale manufacturing with design‑for‑manufacture/test support and supply chain coordination.
Integration and testing of thin, solid‑state rechargeable microbatteries for implantable systems, including characterization and production transfer support.
Secure data ingestion from wearable readers, mobile app integration and cloud analytics to generate clinician‑facing IOP (and other physiologic) profiles and alerts.
Partnerships with academic clinical centers for bench, animal and first‑in‑human pilot studies to collect safety and performance data.
Transfer of semiconductor‑based implant designs to wafer‑scale manufacturing with design‑for‑manufacture/test support and supply chain coordination.
Integration and testing of thin, solid‑state rechargeable microbatteries for implantable systems, including characterization and production transfer support.
Secure data ingestion from wearable readers, mobile app integration and cloud analytics to generate clinician‑facing IOP (and other physiologic) profiles and alerts.
Expertise Areas
- Implantable medical devices
- Continuous physiologic monitoring
- MEMS and ASIC integration
- Microbattery and energy storage for implants
Key Technologies
- MEMS pressure sensors
- Solid‑state rechargeable microbatteries
- Ultra‑low power ASICs / IC design
- Wireless telemetry and wireless power transfer
News & Updates
The first human implant and wireless IOP measurements using Injectsense's FDA breakthrough-designated sensor, demonstrating feasibility and safety.
FDA designation for its chronic continuous IOP monitoring system, enabling priority review and clinical development.
Funding to support the development and manufacturing of autonomous implantable sensors and microbatteries for long-term disease monitoring.
Discusses how continuous, high-fidelity IOP data from implantable sensors can enable AI analysis for better glaucoma management.
Highlights the importance of continuous IOP monitoring for AI applications in glaucoma, moving beyond sporadic measurements.
Received in 2020 for its chronic continuous IOP monitoring system, facilitating faster development and approval.
The first human implant and wireless IOP measurements using Injectsense's FDA breakthrough-designated sensor, demonstrating feasibility and safety.
FDA designation for its chronic continuous IOP monitoring system, enabling priority review and clinical development.
Funding to support the development and manufacturing of autonomous implantable sensors and microbatteries for long-term disease monitoring.
Discusses how continuous, high-fidelity IOP data from implantable sensors can enable AI analysis for better glaucoma management.
Highlights the importance of continuous IOP monitoring for AI applications in glaucoma, moving beyond sporadic measurements.
Received in 2020 for its chronic continuous IOP monitoring system, facilitating faster development and approval.